Tower Research Capital LLC (Trc) Corvus Pharmaceuticals, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $3.29 Billion
- Q1 2025
A detailed history of Tower Research Capital LLC (Trc) transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 2,999 shares of CRVS stock, worth $13,495. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,999
Previous 13,822
78.3%
Holding current value
$13,495
Previous $71,000
87.32%
% of portfolio
0.0%
Previous 0.0%
Shares
30 transactions
Others Institutions Holding CRVS
# of Institutions
113Shares Held
39.9MCall Options Held
1.37MPut Options Held
338K-
Orbimed Advisors LLC San Diego, CA6.94MShares$31.2 Million0.69% of portfolio
-
Samlyn Capital, LLC New York, NY4.07MShares$18.3 Million0.21% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.28MShares$14.8 Million0.0% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$14.7 Million9.69% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.79MShares$12.5 Million0.02% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $209M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...